Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Dureau-Pournin, C.
62  Ergebnisse:
Personensuche X
?
1

Cardiovascular or renal disease (CVRD) complication and mor..:

Jourdain, P. ; Blin, P. ; Zaoui, P....
Archives of Cardiovascular Diseases Supplements.  15 (2023)  1 - p. 110 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Cardiovascular or renal disease (CVRD) complication and mor..:

Jourdain, P ; Blin, P ; Zaoui, P...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
3

Should dual antiplatelet therapy be maintained beyond one y..:

Blin, P ; Danchin, N ; Benichou, J...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
4

EE600 Cumulative Cardiovascular or Renal Disease (CVRD) Hos..:

Blin, P ; Zaoui, P ; Joubert, M...
Value in Health.  25 (2022)  12 - p. S173 , 2022
Link: https://doi.org/10.1016/..
 
?
5

Real world risk of major outcomes for type 2 diabetes with ..:

Blin, P ; Darmon, P ; Henry, P...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
6

Prevalence of type 2 diabetes with stable coronary artery d..:

Blin, P ; Darmon, P ; Henry, P...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
7

Effectiveness and safety of standard and reduced dosages of..:

Blin, P. ; Cottin, Y. ; Dureau-Pournin, C....
Archives of Cardiovascular Diseases Supplements.  11 (2019)  1 - p. 120-121 , 2019
Link: https://doi.org/10.1016/..
 
?
8

P4820Benefit-risk of rivaroxaban 20 or 15mg compared to vit..:

Moore, N ; Fauchier, L ; Sacher, F...
European Heart Journal.  39 (2018)  suppl_1 - p. , 2018
Link: https://doi.org/10.1093/..
 
?
9

DS2 - EFFECTIVENESS AND SAFETY OF STANDARD AND REDUCED DOSE..:

Blin, P. ; Cottin, Y. ; Dureau-Pournin, C....
Value in Health.  21 (2018)  - p. S7 , 2018
Link: https://doi.org/10.1016/..
 
?
10

P3851Benefit-risk profile of dabigatran compared with vitam..:

Cottin, Y ; Blin, P ; Benichou, J...
European Heart Journal.  39 (2018)  suppl_1 - p. , 2018
Link: https://doi.org/10.1093/..
 
?
11

Risk factors for the primary effectiveness endpoint in seco..:

Danchin, N. ; Blin, P. ; Falissard, B....
Archives of Cardiovascular Diseases Supplements.  10 (2018)  1 - p. 9 , 2018
Link: https://doi.org/10.1016/..
 
?
12

Benefit-Risk And Medical Costs of Rivaroxaban 15mg Versus V..:

Blin, P ; Fauchier, L ; Dallongeville, J...
Value in Health.  20 (2017)  9 - p. A608 , 2017
Link: https://doi.org/10.1016/..
 
?
13

3112Effectiveness and safety of ticagrelor compared with cl..:

Danchin, N. ; Blin, P. ; Falissard, B....
European Heart Journal.  38 (2017)  suppl_1 - p. , 2017
Link: https://doi.org/10.1093/..
 
?
14

Benefit-Risk And Medical Costs of Rivaroxaban 20mg Versus V..:

Blin, P ; Fauchier, L ; Dallongeville, J...
Value in Health.  20 (2017)  9 - p. A608 , 2017
Link: https://doi.org/10.1016/..
 
?
15

Comparative Effectiveness And Medical Cost of Dabigatran Ve..:

Blin, P ; de Pouvourville, G ; Cottin, Y...
Value in Health.  20 (2017)  9 - p. A608-A609 , 2017
Link: https://doi.org/10.1016/..
 
1-15